IML Conc Aus Shares Fund (Quoted Managed Fund)

IMLC

IMLC.AX was created on 2023-08-01 by IML. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to outperform the S&P/ASX 300 Accumulation Index (after fees and expenses and before taxes) on a rolling four-year basis.

Immutep Limited

IMM

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.

Imdex Limited

IMD

Imdex Ltd. engages in the provision of mining equipment, technology, and services. The company is headquartered in Balcatta, Western Australia and currently employs 816 full-time employees. The Company’s product offering includes an integrated range of drilling optimization products, cloud connected rock knowledge sensors and data and analytics. Its geographical segments include Americas, Asia Pacific, and Africa/Europe. The Company’s solutions include software, mining technology, drilling optimization, downhole navigation, structural geology, in-field geo-analysis, and driller operable geophysics. Its brands include AMC and REFLEX technologies. Its products include IMDEXHUB-IQ, IMDEX MOBILE, AMC BORE HOLE STABILISER, IMDEX MUD AID, AMC BOS, and AMC SRU Range. Its drilling fluid range include cement & grouting additives, clay & shale stabilizers, drilling fluids equipment, filtrate control agents, flocculants & dispersants, foaming agents & detergents, lost circulation materials, lubricants & cutting oils, specialty products & chemicals, treating chemicals, viscosifiers, and weighting materials.

Imexhs Limited

IME

ImExHS Ltd. engages in the development and sale of its Hiruko software platform. The company is headquartered in Mascot, New South Wales and currently employs 400 full-time employees. The company went IPO on 2005-12-14. The firm develops software-as-a-service imaging solutions that includes a Picture Archiving and Communications System (PACS), a Radiology Information System (RIS), a Cardiology Information System (CIS) and an Anatomical Pathology Laboratory Information System (APLIS). Its solutions are cloud-based, vendor neutral and zero footprint, with no need for installed software. Its radiology services provide radiological diagnostic services to hospitals and medical facilities in Colombia and Spain using IMEXHS medical imaging software. The firm's services business also provides it with medical images and radiologists interpretation and reports to develop artificial intelligence (AI) tools. Its solutions include AQUILA - Radiology, ALULA - Pathology, ANTEROS - cardiology, artificial intelligence and advanced visualization.